Abstract：
UNASSIGNED: The objective of this study was to assess the effectiveness of myoinositol (4 g myoinositol + 400 mcg folic acid/day) compared with metformin (average 1700 mg/day), as well as the combined efficacy of both treatments in managing insulin-resistant polycystic ovary syndrome (PCOS) among women.
UNASSIGNED: We retrospectively analyzed the records of 68 reproductive-age PCOS patients with insulin resistance over a 3-month period. Oral glucose tolerance tests (OGTT) (75 gr) were conducted to measure glucose levels at 0 and 120 min. Moreover, changes in prolactin, thyroid stimulating hormone, high-density lipoprotein, low-density lipoprotein, triglyceride levels, total cholesterol, follicle-stimulating hormone, luteinizing hormone, total testosterone, free testosterone, and dehydroepiandrosterone sulfate (DHEA-S) levels were evaluated pre- and post-treatment over a 3-month period.
UNASSIGNED: Statistically significant improvements were observed in menstrual regularity, body mass index (BMI), modified Ferriman Gallwey scores, OGTT glucose levels at 0 and 120 min, total testosterone, free testosterone, and DHEA-S levels across all groups (p<0.005).
UNASSIGNED: No significant variances were observed in terms of BMI, modified Ferriman Gallwey scores, or androgen levels across the three treatment cohorts. The combination of myoinositol and metformin did not confer additional benefits compared with either treatment alone.
UNASSIGNED: We retrospectively analyzed the records of 68 reproductive-age PCOS patients with insulin resistance over a 3-month period. Oral glucose tolerance tests (OGTT) (75 gr) were conducted to measure glucose levels at 0 and 120 min. Moreover, changes in prolactin, thyroid stimulating hormone, high-density lipoprotein, low-density lipoprotein, triglyceride levels, total cholesterol, follicle-stimulating hormone, luteinizing hormone, total testosterone, free testosterone, and dehydroepiandrosterone sulfate (DHEA-S) levels were evaluated pre- and post-treatment over a 3-month period.
UNASSIGNED: Statistically significant improvements were observed in menstrual regularity, body mass index (BMI), modified Ferriman Gallwey scores, OGTT glucose levels at 0 and 120 min, total testosterone, free testosterone, and DHEA-S levels across all groups (p<0.005).
UNASSIGNED: No significant variances were observed in terms of BMI, modified Ferriman Gallwey scores, or androgen levels across the three treatment cohorts. The combination of myoinositol and metformin did not confer additional benefits compared with either treatment alone.
摘要：
■本研究的目的是评估肌醇（4g肌醇+400mcg叶酸/天）与二甲双胍（平均1700mg/天）相比的有效性，以及两种治疗方法在治疗女性胰岛素抵抗多囊卵巢综合征（PCOS）方面的综合疗效。
■我们回顾性分析了68名生育年龄PCOS患者在3个月内出现胰岛素抵抗的记录。进行口服葡萄糖耐量试验（OGTT）（75gr）以测量0和120分钟的葡萄糖水平。此外，催乳素的变化，促甲状腺激素,高密度脂蛋白，低密度脂蛋白，甘油三酯水平，总胆固醇,促卵泡激素,黄体生成素,总睾酮,游离的睾酮,和硫酸脱氢表雄酮（DHEA-S）水平在3个月的治疗前和治疗后进行评估。
■在月经规律方面观察到统计学上的显着改善，体重指数（BMI），FerrimanGallwey修改分数,OGTT葡萄糖水平在0和120分钟，总睾酮,游离的睾酮,所有组的DHEA-S水平(p<0.005)。
■在BMI方面没有观察到显著差异，FerrimanGallwey修改分数,或三个治疗组的雄激素水平。肌醇和二甲双胍的组合与单独的任一治疗相比没有带来额外的益处。
■我们回顾性分析了68名生育年龄PCOS患者在3个月内出现胰岛素抵抗的记录。进行口服葡萄糖耐量试验（OGTT）（75gr）以测量0和120分钟的葡萄糖水平。此外，催乳素的变化，促甲状腺激素,高密度脂蛋白，低密度脂蛋白，甘油三酯水平，总胆固醇,促卵泡激素,黄体生成素,总睾酮,游离的睾酮,和硫酸脱氢表雄酮（DHEA-S）水平在3个月的治疗前和治疗后进行评估。
■在月经规律方面观察到统计学上的显着改善，体重指数（BMI），FerrimanGallwey修改分数,OGTT葡萄糖水平在0和120分钟，总睾酮,游离的睾酮,所有组的DHEA-S水平(p<0.005)。
■在BMI方面没有观察到显著差异，FerrimanGallwey修改分数,或三个治疗组的雄激素水平。肌醇和二甲双胍的组合与单独的任一治疗相比没有带来额外的益处。
